Qualyst and Hepregen Launch HepatoPac® B-CLEAR® Transporter Product
Product News Apr 21, 2015
Qualyst Transporter Solutions, LLC (Qualyst) and Hepregen Corporation have announced, at the American Association of Pharmaceutical Scientists/International Transporter Consortium ("AAPC/ITC") Joint Workshop on Drug Transporters, the launch of their first co-developed and co-labeled transporter kit for in vitro analysis of chemical transporter proteins in the human liver.
The launch of this first application-directed HepatoPac® B-CLEAR® assay kit, provides a product to investigators that can be routinely used for predictive and mechanistic hepatic transporter analysis. This first co-launched kit contains human hepatocytes (liver cells) in Hepregen's proprietary micro-patterned, co-culture microtiter tissue culture plates and Qualyst's proprietary transporter culture media. The co-cultures are optimized for transporter analysis using Qualyst's proprietary hepatobiliary methodology.
Moreover, as a part of this launch effort, both companies are continuing their commitment to providing unequaled customer support. Hepregen scientists bring years of experience evaluating metabolite and toxicology data developed using the HepatoPac® platform, and Qualyst scientists provide a wealth of experience interpreting results of measuring concentrations of new chemical entities and their metabolites inside hepatocytes, bile canaliculi and cell culture medium.
"The rapid development of our co-labeled product is the result of an exceptional collaborative effort," said Christopher Black, Qualyst's chief executive officer. "Now we can offer Qualyst's patented and proven B-CLEAR® technology to our customers via a best-in-class HepatoPac® B-CLEAR® transporter kit or as a service provided at our dedicated North Carolina laboratory using this high performance product."
"This partnership with Qualyst is an example of Hepregen's commitment to working with premier companies in the industry to provide real solutions to scientists developing new drugs and chemical entities," commented Dr. Vincent Zurawski, Hepregen's president and chief executive, adding, "The unique capabilities of the HepatoPac® platform and the proprietary capabilities of the Qualyst B-CLEAR® system have been combined to yield an unmatched level of performance in this first co-developed kit."